Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations

References

• RabeKFHurdSAnzuetoAGlobal Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med200717653255517507545
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J20042393294615219010
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJAmerican Thoracic Society; European Respiratory Society Task Force on outcomes of COPDOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J20083141646918238951
   PubMed Web of Science ®Google Scholar
• KestenSJaraMWentworthCLanesSPooled clinical trial analysis of tiotropium safetyChest20061301695170317166984
   PubMed Web of Science ®Google Scholar
• FergusonGTFunck-BrentanoCFischerTDarkenPReisnerCCardiovascular Safety of Salmeterol in COPDChest20031231817182412796155
   PubMed Web of Science ®Google Scholar
• RodrigoGJNanniniLJRodriguez-RoisinRSafety of long-acting beta-agonists in stable COPD: a systematic reviewChest20081331079108718460518
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once-daily tiotropium compared with twice-daily salmeterol in patients with COPDThorax20035839940412728159
   PubMed Web of Science ®Google Scholar
• BriggsDDCovelliHLapidusRBhattycharyaSKestenSCassinoCImproved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPDPulm Pharmacol Ther20051839740416179215
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med200514331732616144890
   PubMed Web of Science ®Google Scholar
• DusserDBravoMLIaconoPMISTRAL study groupThe effect of tiotropium on exacerbations and airflow in patients with COPDEur Respir J20062754755516507855
   PubMed Web of Science ®Google Scholar
• BeehKMBeierJBuhlRStark-LorenzenPGerkenFMetzdorfNATEM study groupEfficacy of tiotropium bromide (Spiriva®) in patients with chronic obstructive pulmonary disease (COPD) of different severitiesPneumologie20066034134616761228
   PubMedGoogle Scholar
• Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human useOff J Eur Commun2001L1213444
   Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J20021921722411866001
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest2002122475512114338
   PubMed Web of Science ®Google Scholar
• TonnelABPerezTGrosboisJMVerkindreCBravoMLBrunMTIPHON Study GroupEffect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPDInt J COPD20083110
   Google Scholar
• PowrieDJWilkinsonTMADonaldsonGCEffect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPDEur Respir J20073047247817504798
   PubMed Web of Science ®Google Scholar
• ChanCKNMaltaisFSigouinCHaddonJMFordGTSAFE Study GroupA randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary diseaseCan Respir J20071446547218060091
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1998157141814229603117
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax20025784785212324669
   PubMed Web of Science ®Google Scholar
• KannerREAnthonisenNRConnettJELower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health StudyAm J Respir Crit Care Med200116435836411500333
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJMartinez-GarciaMASanchezPRSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax20056092593116055622
   PubMed Web of Science ®Google Scholar
• O’DonnellDEAaronSBourbeauJCanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 updateCan Respir J2007145B32B
   PubMed Web of Science ®Google Scholar
• KardosPWenckerMGlaabTVogelmeierCImpact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200717514414917053207
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMASeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of COPD exacerbations by salmeterol/ fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
   PubMed Web of Science ®Google Scholar
• Rodriguez-RoisinRToward a consus definition for COPD exacerbationsChest2000117398S401S10843984
   PubMed Web of Science ®Google Scholar
• AaronSDFergussonDMarksGBCanadian Thoracic Society/ Canadian Respiratory Clinical Research ConsortiumCounting, analysing and reporting exacerbations of COPD in randomized controlled trialsThorax20086312212817702790
   PubMed Web of Science ®Google Scholar
• McGarveyLPJohnMAndersonJAZvarichMWiseRAAscertainment of cause-specific mortality in COPD: Operations of the TORCH Clinical Endpoint CommitteeThorax20076241141517311843
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBTashkinDPClinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift TrialCOPD2004130331217136995
   PubMedGoogle Scholar
• SuissaSStatistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200617384284616439716
   PubMed Web of Science ®Google Scholar
• SuissaSErnstPVandemheenKLAaronSDMethodological issues in therapeutic trials of COPDEur Respir J20083192793318216056
   PubMed Web of Science ®Google Scholar